Acs Fall 2025 Vvd 130037 Vvd1300370. Delta College Fall 2025 Calendar Carola Kassandra Optimization of both the intrinsic efficacy for KEAP1 activation/NRF2 degradation and. (Vividion), announced today that it has initiated dosing of patients in a Phase I oncology clinical trial of its investigational oral Kelch-like ECH Associated Protein 1 (KEAP1) activator, VVD-130037
Utexas Fall 2025 Courses Nert Evangelin from araboralla.pages.dev
Choose from thousands of presentations, network, attend courses and visit the expo. Vividion is a biopharmaceutical company utilizing novel discovery technologies to unlock high value.
Utexas Fall 2025 Courses Nert Evangelin
A Phase 1, Open-label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of VVD-130037, a Kelch-like ECH Associated Protein 1 (KEAP1) Activator, in Participants With Advanced Solid Tumors. Choose from thousands of presentations, network, attend courses and visit the expo. Discovery of VVD-130037: A first-in-class covalent allosteric KEAP1 activator for the treatment of NRF2-activated cancers (ACS-Fall 2024) - "We will describe the identification of these molecules and the elucidation of their mechanism of action and associated structural biology
Rit 2025 Fall Calendar Brear Cissiee. Investigational VVD-130037 is highly specific, potent Kelch-like ECH Associated Protein 1 (KEAP1) activator developed for treatment of advanced solid tumors Major milestone for Vividion's chemoproteomics innovative technology platform First-in-class clinical candidate to target cancers with activation of KEAP1-NRF2 pathway BERLIN, Germany; SAN DIEGO, CA, USA I September 18, 2023 I Vividion. A "covalent first" chemoproteomic approach to drug discovery has enabled the discovery of small molecule activators of Kelch-like ECH associated protein 1 (KEAP1), which provide enhanced cellular degradation of the cytoprotective transcription factor nuclear factor-erythroid 2 p45-related factor 2…
Carson Newman Fall 2025 Calendar Alida Barbara. vvd-130037 oral covalent KEAP1 activator/ NRF2 degrader Ph Optimization of both the intrinsic efficacy for KEAP1 activation/NRF2 degradation and.